Navigation Links
Smith & Nephew Announces Agreement with the OREF Regarding Grants to Support Research and Education in Orthopaedics

MEMPHIS, Tenn., Jan. 30 /PRNewswire-FirstCall/ -- Smith & Nephew, Inc. (NYSE: SNN, LSE: SN) announced today that its Orthopaedics Reconstruction Division has entered into a grant administration agreement with the Orthopaedic Research and Education Foundation (OREF).

Under the agreement, Smith & Nephew's first with a third-party administrator of grants, OREF will assist Smith & Nephew in continuing its long-standing support of research and education in orthopaedics. The multi-year agreement is unique among the major joint replacement makers in that it covers graduate medical education, including fellowships and residency enhancement programs, as well as continuing medical education (CME) and research. This comprehensive approach gives Smith & Nephew a platform from which to support consistent education and innovation in orthopaedics.

"Smith & Nephew is dedicated to the advancement of orthopaedic innovation, education and patient care," said Joseph M. DeVivo, President of Smith & Nephew Orthopaedics Reconstruction & Trauma Division. "Formalizing our relationship with OREF allows Smith & Nephew to continue supporting orthopaedic research and education in a comprehensive way while working with an organization dedicated to its mission, independence, and integrity. OREF's history of working productively with many orthopaedic societies and institutions makes this an especially good choice."

Under the agreement, which has been approved by Smith & Nephew's government-appointed monitor, OREF will help Smith & Nephew establish its annual research and education support goals, ensure the highest standards of professionalism and independence for distribution of those funds, and provide regular reports on the results of those donations, including a detailed annual summary of donation distribution.

"This agreement benefits Smith & Nephew, orthopaedic researchers and educators, and most importantly, the patients who rely on quality orthopaedic care," said Dr. William Cooney, Chairman of the Board of Trustees of OREF. "This agreement will facilitate industry support for critical research and educational programs and will serve as a model for other corporations seeking to support orthopaedic research and education while avoiding conflicts of interest. We are very proud of OREF's long-standing commitment to the orthopaedic specialty, and are especially pleased to work with Smith & Nephew to move into a new era of service."

About Smith & Nephew

Smith & Nephew is a global medical technology business, specialising in Orthopaedics, including Reconstruction, Trauma and Clinical Therapies; Endoscopy and Advanced Wound Management. Smith & Nephew is a global leader in arthroscopy and advanced wound management and is one of the leading global orthopaedics companies.

Smith & Nephew is dedicated to helping improve people's lives. The Company prides itself on the strength of its relationships with its surgeons and professional healthcare customers, with whom its name is synonymous with high standards of performance, innovation and trust. The company operates in 32 countries around the world generating annual sales of nearly $3.4 billion.

About OREF

OREF is a fifty-three year old independent, non-profit organization that was created specifically to receive donations from individuals and companies to foster research and education in orthopaedics. Since its inception, OREF has made approximately 3,200 grants totaling nearly $88 million to individuals and organizations. OREF's independent peer review process to evaluate grant applications is based on the standards of the National Institutes of Health (NIH).

Forward-Looking Statements

This press release contains certain "forward-looking statements" within the meaning of the US Private Securities Litigation Reform Act of 1995. In particular, statements regarding planned growth in our business and in our trading margins discussed under "Outlook" are forward-looking statements as are discussions of our product pipeline. These statements, as well as the phrases "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions, are generally intended to identify forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors (including, but not limited to, the outcome of litigation and regulatory approvals) that could cause the actual results, performance or achievements of Smith & Nephew, or industry results, to differ materially from any future results, performance or achievements expressed or implied by such forward-looking statements. Please refer to the documents that Smith & Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith & Nephew's most recent annual report on Form 20F, for a discussion of certain of these factors.

All forward-looking statements in this press release are based on information available to Smith & Nephew as of the date hereof. All written or oral forward-looking statements attributable to Smith & Nephew or any person acting on behalf of Smith & Nephew are expressly qualified in their entirety by the foregoing. Smith & Nephew does not undertake any obligation to update or revise any forward-looking statement contained herein to reflect any change in Smith & Nephew's expectation with regard thereto or any change in events, conditions or circumstances on which any such statement is based.

SOURCE Smith & Nephew, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Smithfield Foods Lean Generation(R) Deli Partnership with National Breast Cancer Foundation Celebrates $135,000 Contribution
2. GlaxoSmithKline and Genmab Submit Arzerra(TM) (Ofatumumab) Application to FDA for the Treatment of Advanced Stage Blood Cancer
3. Houlihan Smith Arranges Equity Investment Into Tri-Tech Health, LLC
4. Orthopaedic Surgeon Kevin Smith, MD, Joins Northwest Hospital & Medical Center and The Sports Medicine Clinic
5. GlaxoSmithKlines Drug Will Become New Clinical Gold Standard by 2012 for the Treatment of Relapsed/Refractory CLL
6. GlaxoSmithKline Awards Ten Area Healthcare Nonprofits with $40,000 Each in Funding
7. Smith & Nephew Advanced Wound Management Comments on Temporary Injunction in United Kingdom
8. GlaxoSmithKline and Dynavax Announce Worldwide Strategic Alliance : – Developing First-in-Class Endosomal TLR Inhibitors for Autoimmune and Inflammatory Diseases –
9. Noland Named Vice President, Board & CEO Services for B. E. Smith
10. GlaxoSmithKline Statement on FDA Advisory Committee Vote on Use of Asthma Medicines Containing Long-Acting Beta-Agonists
11. 20,000,000th Phone Order Placed at Doctors Foster & Smith Pet Supplies
Post Your Comments:
(Date:12/1/2015)... ... ... The Multiple System Atrophy Coalition has announced the launch of its MSA Can’t ... today to coincide with Giving Tuesday 2015, a global day of fundraising. , ... be productive, to do simple daily activities like walking to the mailbox and eating ...
(Date:12/1/2015)... ... December 01, 2015 , ... Royal River Natural Foods — a locally-owned, ... post-menopausal women who took the nutritional supplement creatine, along with resistance training for a ... not take creatine. , The report is part of the December 2015 issue of ...
(Date:12/1/2015)... ... 2015 , ... Baptist Medical Center Jacksonville has implanted the ... hospital in the region providing what is known as the world’s smallest pacemaker. ... revealed recently at a medical conference and published in The New England Journal ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... to continue the expansion of the company’s growing product line of food safety ... (Oncorhynchus tshawytscha) and Sockeye (Oncorhynchus nerka) – allow InstantLabs to offer fast, reliable ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... the United States. Podiatrists are well aware that psychology-based patient non-compliance (disobedience of ... often catastrophic contributors to diseases of the diabetic foot. The American Board ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... 1, 2015  Eyeon Therapeutics has received a ... treatments based on a charged hydrophilic polymer developed ... The product has been shown to be safe ... Mark Mitchnick , MD, CEO states, "This ... additional polymers in conjunction with a therapeutic agent.  ...
(Date:12/1/2015)... 1, 2015  Athletic apparel company Tommie ... to pay $1.35 million to settle Federal Trade ... copper-infused compression clothing would relieve severe and chronic ... diseases. Tommie Copper,s proposed ... and its founder and chairman Thomas Kallish ...
(Date:12/1/2015)... diciembre de 2015  AccuTEC Blades, una ... precisión, develó hoy un nuevo logo corporativo ... El nuevo logo destaca la experiencia de ... de productos con cuchillas donde "el borde ... --> ...
Breaking Medicine Technology: